Inovio Pharmaceuticals Inc. (NASDAQ:INO) changes shares on Wednesday trading session, with a change of 10.66% or $2.3 shares. The trading starts at $22.12 and closed at $21.57 throughout the day. The trading session low price was $20.63 and day high was $25.60 on Wednesday, June 24. After the session, the Healthcare sector daily volume shifted to 124.76 million while its average volume is 31.31M. In other hand, the INO market cap reached to $3.79B. While, its current target price is $23.87 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 72.72% and up 65.08% for month. Its quarterly performance was 257.34% above, while its half year performance is up 541.67%. INO yearly performance stood at positive 847.22% and rise 623.33% for year-to-date. Current recommendation for Inovio Pharmaceuticals Inc. is 2.20.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. INO EPS (TTM) for 12-month is -1.17. EPS for this year is -15.40%, while for the next year its value is 0.48. Its EPS Q/Q reached 12.90%. It has an EPS of -14.60% down for past five years and for the next five years will be down 0.00%.
Let’s take a look on the analyst recommendations on INO for the current month and previous month. For the current month, 5 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 3 as Hold. As compared with the previous month ratings, 7 analysts participate in stock recommendation. Out of 7, 0 rated it sell, 4 rated it as Buy and 3 as Hold Ratings. On the other hand, target price ranges from $8.00-$28.00. Average target price for INO was reached at $16.75.
The insider ownership moved to 1.60% and institutional holding shifted to 26.60%.
The company posted an EPS (TTM) of -1.17. According to the most recent quarter report on (Jun 2020), 8 analysts estimated an average EPS of -0.17, while -0.3 EPS posted a year ago period. Analyst Estimated EPS for INO published in the report was -0.19–0.16 during the same period. Comparing with last year, the average estimated EPS was -0.3 which is lower than -0.26 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for INO rise 292.51% for period of 200 days. SMA for 50 days was 87.83% which is showing green signal, while SMA-20 was 72.06%. The moving average value for Inovio Pharmaceuticals Inc. (INO) is 7.96 and 13.88 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in INO stock. On Jun 22, Humeau Laurent, Chief Scientific Officer, sold 19,467 trading shares at the cost of $14.70, which valued at 0.29 million. On May 20, BENITO SIMON X, Director, sold 8,750 shares at the cost of $15.95, with total shares of 51,650. On May 11, Weiner David B., Director, sold 2,404 shares at the cost of 11.84. After this transaction, Weiner David B. total shares reached to 827,219 which valued at 28463.0.